ProMIS Neurosciences Inc.

Snapshot

ProMIS is a clinical-stage biotech with no product revenue, developing an Alzheimer's antibody (PMN310) now in a Phase 1b trial. FY 2025 net loss was $39.7M and operating cash flow was -$28.1M.

What's Happening Right Now

• Tue 6th Oct '26 · Executive hire: On Oct 6, 2026, ProMIS appointed Ivana Rubino, Ph.D. as Chief Commercial Officer to lead launch-readiness for PMN310 ahead of the 12-month PRECISE-AD data expected in Q1 2027; she received an inducement option for 80,000 shares at $9.37.
• Fri 14th Aug '26 · Earnings/trial data: On Aug 13, 2026, ProMIS reported Q2 2026 results with a $11.7M net loss, $53.4M cash and short-term investments after a $70.1M January private placement, and positive blinded 6-month interim PRECISE-AD data for PMN310 showing zero ARIA-E cases across 136 participants.
• Thu 13th Aug '26 · 10-Q filing: ProMIS's Q2 2026 10-Q (filed Aug 13, 2026) showed a $20.0M first-half net loss, an accumulated deficit of $150.4M, operating cash burn more than doubling to $22.8M from $8.8M a year earlier, 8.97M shares outstanding, and 9.34 million warrants outstanding creating a sizable dilution overhang.
• Thu 2nd Apr '26 · Registration: Registered $200.00M of securities for sale on Form S-3.
• Thu 26th Mar '26 · Registration: Registered 13.83M shares for sale on Form S-3.
• Thu 29th Jan '26 · Offering: Raised $75.50M in gross proceeds through a private placement (PIPE), with warrants over 7.02M shares.